WHO and other stakeholders join forces to accelerate access to effective paediatric HIV and tuberculosis diagnostics and medicines

On World Children’s Day, WHO is pleased to issue a call urging stakeholders to accelerate access to effective paediatric HIV and tuberculosis (TB) diagnostics and medicines.

The Action Plan, which is launched today, has been developed by a wide group of stakeholders under the auspices of the Fifth Vatican High-Level Dialogue on Paediatric HIV and TB in Children Living with HIV which was held earlier this month.     

Children are one of the most disadvantaged populations in the HIV and AIDS and TB response. In 2019, 95 000 AIDS-related deaths occurred in children, two-thirds of those deaths in 21 focus countries. 850 000 children living with HIV were not
accessing treatment, 65% of which were aged 5-14 years. These children are also particularly susceptible to co-infection with tuberculosis, a major cause of AIDS-related deaths in this population. In 2019, an estimated 36 000 children who were
living with HIV died from TB.

There are several challenges that hamper the rapid development of paediatric formulations, including lack of paediatric data for new drugs, delay in completion of clinical studies, challenges with taste, and slow market uptake among others. In addition,
high prices of diagnostic products, limited availability and accessibility to novel technical and case-finding interventions as well as fragmented and delayed regulatory approvals are some of the challenges faced in finding appropriate diagnostics
for children. All in all these delay and affect uptake of essential services to diagnose and treat children with HIV and TB.

The plan agreed upon by participants of the High Level Dialogue includes pledges to accelerate development of new pediatric HIV and TB formulations; improved diagnostic devices and assays for children with TB; and lower prices for early infant HIV diagnosis.

Researchers and pharmaceutical companies have committed to continue and expand their collaborations to investigate and develop better medicines for children. Regulators committed to work towards facilitating the regulatory pathways for priority TB and HIV paediatric medicines. Government representatives confirmed their support for advancing widespread availability of new tests and optimal paediatric medicines.
Policymakers committed to continue updating their normative work to capture new developments and support prioritization of research and development for medicines and diagnostics. Finally, key donors expressed their commitment by continuing and expanding
their investments to support development of better formulations for children.

Organizers of the High-Level Dialogue included WHO and the Elizabeth Glaser Paediatric Aids Foundation, in their capacity as co-chairs of the AIDS Free Working Group of the Start Free, Stay Free, AIDS Free framework, as well as The US President’s Emergency
Plan for AIDS Relief (PEPFAR), UNAIDS, representatives of faith-based organizations, and the Stop TB partnership. Participants included leaders of major diagnostic and pharmaceutical companies, multilateral organizations, governments, regulators,
faith-based organizations, and services providers for children and adolescents living with HIV and TB.

The 2020 High-Level Dialogue serves as a reminder of the challenges that exist, but also highlights the opportunities we can capitalize on when we work together.  WHO remains committed in working with its partners in ensuring progress towards a Start
Free, Stay Free and AIDS Free generation and to reaching the targets as included in the political declaration of the UN General Assembly High Level Meeting on TB and the WHO End TB Strategy

“The impact of the COVID-19 pandemic has laid bare the power of collaboration and partnership to accelerate action. The WHO Global HIV programme recognizes this Action Plan as the roadmap to reset the speed at which innovations in drugs and diagnostics
can lead to child-centered impact. We are proud to commit to developing the norms and standards, policies and research agendas on this pathway to success” said Dr Meg Doherty, Director the WHO Global HIV, Hepatitis and STI Programmes.

On World Children’s Day, WHO is pleased to issue a call urging stakeholders to accelerate access to effective paediatric HIV and tuberculosis (TB) diagnostics and medicines.

The Action Plan, which is launched today, has been developed by a wide group of stakeholders under the auspices of the Fifth Vatican High-Level Dialogue on Paediatric HIV and TB in Children Living with HIV which was held earlier this month.     

Children are one of the most disadvantaged populations in the HIV and AIDS and TB response. In 2019, 95 000 AIDS-related deaths occurred in children, two-thirds of those deaths in 21 focus countries. 850 000 children living with HIV were not
accessing treatment, 65% of which were aged 5-14 years. These children are also particularly susceptible to co-infection with tuberculosis, a major cause of AIDS-related deaths in this population. In 2019, an estimated 36 000 children who were
living with HIV died from TB.

There are several challenges that hamper the rapid development of paediatric formulations, including lack of paediatric data for new drugs, delay in completion of clinical studies, challenges with taste, and slow market uptake among others. In addition,
high prices of diagnostic products, limited availability and accessibility to novel technical and case-finding interventions as well as fragmented and delayed regulatory approvals are some of the challenges faced in finding appropriate diagnostics
for children. All in all these delay and affect uptake of essential services to diagnose and treat children with HIV and TB.

The plan agreed upon by participants of the High Level Dialogue includes pledges to accelerate development of new pediatric HIV and TB formulations; improved diagnostic devices and assays for children with TB; and lower prices for early infant HIV diagnosis.

Researchers and pharmaceutical companies have committed to continue and expand their collaborations to investigate and develop better medicines for children. Regulators committed to work towards facilitating the regulatory pathways for priority TB and HIV paediatric medicines. Government representatives confirmed their support for advancing widespread availability of new tests and optimal paediatric medicines.
Policymakers committed to continue updating their normative work to capture new developments and support prioritization of research and development for medicines and diagnostics. Finally, key donors expressed their commitment by continuing and expanding
their investments to support development of better formulations for children.

Organizers of the High-Level Dialogue included WHO and the Elizabeth Glaser Paediatric Aids Foundation, in their capacity as co-chairs of the AIDS Free Working Group of the Start Free, Stay Free, AIDS Free framework, as well as The US President’s Emergency
Plan for AIDS Relief (PEPFAR), UNAIDS, representatives of faith-based organizations, and the Stop TB partnership. Participants included leaders of major diagnostic and pharmaceutical companies, multilateral organizations, governments, regulators,
faith-based organizations, and services providers for children and adolescents living with HIV and TB.

The 2020 High-Level Dialogue serves as a reminder of the challenges that exist, but also highlights the opportunities we can capitalize on when we work together.  WHO remains committed in working with its partners in ensuring progress towards a Start
Free, Stay Free and AIDS Free generation and to reaching the targets as included in the political declaration of the UN General Assembly High Level Meeting on TB and the WHO End TB Strategy. 

“The impact of the COVID-19 pandemic has laid bare the power of collaboration and partnership to accelerate action. The WHO Global HIV programme recognizes this Action Plan as the roadmap to reset the speed at which innovations in drugs and diagnostics
can lead to child-centered impact. We are proud to commit to developing the norms and standards, policies and research agendas on this pathway to success” said Dr Meg Doherty, Director the WHO Global HIV, Hepatitis and STI Programmes.

Next Post

World leaders join forces to fight the accelerating crisis of antimicrobial resistance

Jum Nov 20 , 2020
<p>The heads of the Food and Agriculture Organization of the United Nations (FAO), the World Organisation for Animal Health (OIE), and the World Health Organization (WHO) today launched the new One Health Global Leaders Group on Antimicrobial Resistance. </p><p>Group members include heads of government, government ministers, leaders from private sector and civil society. The group is co-chaired by their Excellencies Mia Mottley, Prime Minister of Barbados, and Sheikh Hasina Wazed, Prime Minister of Bangladesh.  </p><p>The full list of the members of the One Health Global<strong> </strong>Leaders Group is available <a href="https://www.who.int/groups/one-health-global-leaders-group-on-antimicrobial-resistance">here</a>. </p><p>The group will harness the leadership and influence of these world-renowned figures to catalyze global attention and action to preserve antimicrobial medicines and avert the disastrous consequences of antimicrobial resistance.</p><p>The <a href="https://www.who.int/foodsafety/areas_work/antimicrobial-resistance/tripartite/en/">Tripartite</a> organizations launched the group during <a href="https://www.who.int/news-room/events/detail/2020/11/18/default-calendar/world-antimicrobial-awareness-week-2020">World Antimicrobial Awareness Week</a> 2020 (18-24 November), as part of their shared call for united action to preserve and protect antimicrobial medicines. The group was created in response to a recommendation from the <a href="https://www.oie.int/fileadmin/Home/eng/Media_Center/docs/pdf/IACG2019/IACG_final_report_EN.pdf">Interagency Coordination Group on Antimicrobial Resistance</a> and supported by the Secretary-General of the United Nations.</p><p>The Directors General described the rapid rise of antimicrobial resistance as one of the world’s most urgent threats to human, animal, plant and environmental health – endangering food security, international trade, economic development and undermining progress towards the Sustainable Development Goals (SDGs). <a href="https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance">Antimicrobial resistance also leads to increased health care costs, hospital admissions, treatment failure, severe illness and death. </a></p><p><strong>Preventing the most severe outcomes of antimicrobial resistance</strong> </p><p>Antimicrobial resistance is making many infections harder to treat worldwide. WHO’s <a href="https://www.who.int/news/item/01-06-2020-record-number-of-countries-contribute-data-revealing-disturbing-rates-of-antimicrobial-resistance">latest reporting</a> shows that the world is running out of effective treatments for several common infections. <br></p><p>“Antimicrobial resistance is one of the greatest health challenges of our time, and we cannot leave it for our children to solve,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “Now is the time to forge new, cross-sector partnerships that will protect the medicines we have and revitalize the pipeline for new ones.” <br></p><p><strong>A common agenda across human, animal and plant health </strong></p><p>Misuse and overuse of antimicrobials in humans, animals and agriculture are the main drivers of antimicrobial resistance.<strong> </strong>Resistant micro-organisms can spread between humans, animals or the environment, and the antimicrobial medicines used to treat various infectious diseases in animals and humans are often the same. </p><p>“No single sector can solve this problem alone,” said QU Dongyu, Director-General of FAO. “Collective action is required to address the threat of antimicrobial resistance – across different economic sectors and country borders.”<s></s></p><p><strong>Elevating political leadership for good governance</strong></p><p>The group will provide political leadership to address this critical global challenge. </p><p>It will elevate the need to prioritize best practices to address antimicrobial resistance at global, regional, and national levels. And it will advise and advocate for  the development and implementation of polices and legislation to govern the importation, manufacture, distribution and use of quality antimicrobial drugs across all sectors.</p><p>“Antimicrobial resistance is a current problem affecting  animal health, human health, and the environment, we need to act today to protect their efficacy,” said Dr Monique Eloit, Director General of OIE. “I am confident that this group will advocate powerfully to implement legislation and mobilize key stakeholders to change antimicrobial use practices to protect our collective health and welfare.”</p><p>More information on the work of the Tripartite (FAO/OIE/WHO) is available <a href="https://www.who.int/foodsafety/areas_work/zoonose/concept-note/en/">here</a>. <br><br>For more information on World Antimicrobial Awareness Week, visit <a href="https://www.who.int/news-room/events/detail/2020/11/18/default-calendar/world-antimicrobial-awareness-week-2020">WHO’s campaign page</a>. A full calendar of World Antimicrobial Awareness Week events can be found <a href="https://www.who.int/campaigns/world-antimicrobial-awareness-week/2020/events-calendar">here</a>. </p><p><strong>Note to Editors:</strong></p><p>The Interagency Coordination Group (IACG) on Antimicrobial Resistance was convened by the Secretary-General of the United Nations after the UN High-Level Meeting on Antimicrobial Resistance in 2017 following the request of the 2016 Political Declaration of the High Level Meeting on Antimicrobial Resistance contained in resolution A/RES/71/3. The IACG brought together partners across the UN, international organizations and individuals with expertise across human, animal and plant health, as well as the food, animal feed, trade, development and environment sectors, to formulate a blueprint for the fight against antimicrobial resistance. The Secretariat for the IACG was provided by WHO, with contributions from FAO and OIE. The IACG completed its mandate on 29 April 2019 upon the handover of its report to the UN Secretary-General.<br></p><p><strong>The World Health Organization</strong></p><p>The World Health Organization provides global leadership in public health within the United Nations system. Founded in 1948, WHO works with 194 Member States, across six regions and from more than 150 offices, to promote health, keep the world safe and serve the vulnerable. Our goals for 2019-2023 are to ensure that a billion more people have universal health coverage, to protect a billion more people from health emergencies, and to provide a further billion people with better health and well-being.<br></p><p><strong>The Food and Agriculture Organization</strong></p><p>The Food and Agriculture Organization (FAO) is a specialized agency of the United Nations that leads international efforts to defeat hunger. Our goal is to achieve food security for all and make sure that people have regular access to enough high-quality food to lead active, healthy lives. We believe that everyone can play a part in ending hunger.<br></p><p><strong>The World Organisation for Animal Health</strong></p><p>The OIE is the intergovernmental organisation responsible for improving animal health worldwide. Founded in 1924, it is recognised as a reference organisation for international standards relating to animal health and zoonoses by the World Trade Organization (WTO) and has a total of 182 Member Countries. The OIE maintains permanent relations with international and regional organisations and has Regional and Sub-regional Offices on every continent. <br><strong></strong></p>